GCV Symposium 2017
Skip Content

17 February 2017

Rhythm reaches mezzanine stage to raise $41m

Pfizer and Ipsen returned to reinvest in the metabolic disorder treatment developer, which has now raised $114m altogether.

Author: Robert Lavine, News Editor

US-based peptide therapeutics developer Rhythm closed a $41m mezzanine round yesterday that included pharmaceutical companies Pfizer and Ipsen, the former participating through its Pfizer Venture Investments unit.

Subscribe now

Latest Magazine

Global Corporate Venturing Academy

Editor’s picks

Most popular


23 May 2017

GCV Symposium 2017 - London

Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.

11 April 2017

Canadian Corporate Innovation Summit 2017

April 11 to 13, 2017 at the Fairmont Royal York in Downtown Toronto.

23 April 2017

UniVenture Visions 2017 Symposium – Hong Kong

The Coller Institute of Venture and the AUTM Asia 2017 Conference have announced UniVenture Visions, an exclusive symposium that shall trigger the thinking and discussion necessary to evolve research universities…

More events